How to access Cyltezo (Humira biosimilar) from Bahrain: 2026 pathway via Salmaniya, BDF, and King Hamad University Hospital | Reserve Meds

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

Bahrain treats adalimumab populations across rheumatology, dermatology, gastroenterology, and ophthalmology at Salmaniya Medical Complex, BDF Hospital, and King Hamad University Hospital. The 2026 question for Humira patients is whether to switch to Cyltezo, the FDA interchangeable biosimilar.

Why Cyltezo, why now

Cyltezo (adalimumab-adbm) is a Boehringer Ingelheim biosimilar of the reference biologic Humira (adalimumab). The US FDA approved Cyltezo in August 2017 and granted interchangeability designation in October 2021, making it the first interchangeable adalimumab biosimilar in the United States. The interchangeability designation permits substitution at the pharmacy level (in US states that allow biosimilar substitution) without prescriber intervention. Cyltezo carries the same indications as reference Humira: rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis aged 4 and older, ankylosing spondylitis (AS), psoriatic arthritis (PsA), moderate-to-severe plaque psoriasis (adults and paediatric aged 6 and older), Crohn's disease (adults and paediatric aged 6 and older), ulcerative colitis (adults and paediatric aged 5 and older), hidradenitis suppurativa (adults and paediatric aged 12 and older), and non-infectious uveitis. Dosing is subcutaneous, typically 40 mg every other week after a loading dose, varying by indication and patient weight.

The 2026 question for a Bahrain patient on Humira is whether to switch to Cyltezo to reduce annual drug cost while retaining the same molecular activity. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic. Other US-approved Humira biosimilars include Amjevita (adalimumab-atto), Hyrimoz (adalimumab-adaz), Hadlima (adalimumab-bwwd), Yusimry (adalimumab-aqvh), Cyltezo (interchangeable), Abrilada, Hulio, Idacio, Yuflyma, and others.

What Cyltezo is, in plain language

Cyltezo is a subcutaneous adalimumab biosimilar supplied as a prefilled pen or prefilled syringe. After clinic-supervised training, the patient self-administers at home every other week. Onset of clinical effect is gradual, typically with partial response by week 4 and fuller response by week 12 to 24 depending on indication. Cyltezo is interchangeable with Humira per FDA designation, meaning the molecular activity is clinically equivalent.

Access pathway in Bahrain

Bahrain's National Health Regulatory Authority (NHRA) governs medicine registration, import licensing, and pharmacovigilance under Law 38 of 2009 (Law of Practising the Profession of Pharmacy and Pharmacy Centres). Cyltezo's NHRA registration status is variable; where Cyltezo is not currently NHRA-registered, access runs through the NHRA named-patient personal-import pathway, filed by the treating specialist (rheumatologist, dermatologist, gastroenterologist, or ophthalmologist depending on indication) at Salmaniya Medical Complex (SMC), Bahrain Defence Force (BDF) Hospital, or King Hamad University Hospital (KHUH).

The treating physician submits a named-patient import application documenting the indication, prior treatment history (whether the patient is on Humira and the rationale for switching, or biologic-naive and starting Cyltezo), hepatitis B and TB screening results, and the requested dose and shipment quantity. NHRA reviews and issues an import authorisation per shipment. Reserve Meds sources Cyltezo from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree and chain-of-custody documentation, and ships under validated cold chain to the patient's nominated hospital pharmacy.

Eligibility at a Bahrain specialty clinic

The treating specialist confirms the indication (RA, AS, PsA, plaque psoriasis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, juvenile idiopathic arthritis, or non-infectious uveitis), screens for chronic hepatitis B (HBsAg, anti-HBc, HBV DNA if reactive), latent TB (IGRA or Mantoux plus chest radiograph), and active infection. The patient's vaccination status is reviewed, and any live vaccines are updated before initiation. Pregnancy plans are documented for women of childbearing potential. Heart failure status is assessed (NYHA Class III or IV is a contraindication). For paediatric indications, weight-based dosing is calculated.

Documentation required

The patient and physician should be prepared to provide: a current Bahraini CPR or passport; the specialist's diagnostic file confirming the indication; documentation of prior therapy and response, where applicable; recent hepatitis B serology and TB screening results; recent complete blood count, liver function, renal function; the treating physician's prescription on hospital letterhead; the clinical justification letter; the NHRA named-patient import application; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US export documentation, manufacturer pedigree, and customs packet.

Costs and funding considerations

The annual cost band for Cyltezo in Bahrain is USD 40,000 to 60,000 per patient (BHD 15,000 to 22,000), depending on dose and indication. This is materially lower than the reference Humira annual band. Bahrain's Ministry of Health provides chronic-disease formulary coverage under National Health Insurance for Bahraini nationals, with adalimumab access available case-by-case once eligibility is confirmed. Private insurance carriers active in Bahrain (BUPA Arabia, AXA Cooperative, Daman, Allianz, and Tawuniya regional plans) generally cover adalimumab with pre-authorisation; pharmacy substitution to a Humira biosimilar is increasingly accepted on UM grounds. Reserve Meds will help structure the insurer or MoH submission.

Typical timeline

Weeks 0 to 2: confirm indication, complete hepatitis B and TB screening, prescription preparation, NHRA filing. Weeks 2 to 4: shipment arrival, clinic-supervised injection one to two sessions, patient or caregiver training on pen or syringe technique. Weeks 4 to 12: every-other-week SC at home; partial response by week 4, fuller response by week 12 depending on indication. Months 6 and 12: full reassessment using indication-specific disease activity scores (DAS28 for RA, BASDAI for AS, PASI for psoriasis, etc.).

When Cyltezo is the wrong drug

Active untreated tuberculosis or hepatitis B reactivation risk must be treated first; TNF inhibition is contraindicated until that is addressed. NYHA Class III or IV heart failure is a contraindication. Demyelinating disease (multiple sclerosis, optic neuritis) is a relative contraindication. Active malignancy other than non-melanoma skin cancer is a contraindication. Patients with documented non-response to adalimumab or with neutralising anti-drug antibodies should be considered for an alternative TNF or a different mechanism class (IL-17, IL-23, JAK inhibitor) rather than another adalimumab biosimilar. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic.

Frequently asked questions

• Is the pathway legal in Bahrain? Yes. It operates under NHRA named-patient personal-import authorisation under Law 38 of 2009 and pharmaceutical regulations.
• Will MoH or my insurance cover Cyltezo? Bahraini nationals may secure NHI chronic-disease coverage with documented eligibility; private insurance pre-authorisation is generally available with documented indication.
• Is the molecular activity the same as Humira? Yes; the FDA interchangeability designation confirms clinical equivalence with the reference biologic.
• How is Cyltezo shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Bahrain International Airport.
• Can my child use Cyltezo? Cyltezo is FDA-approved for paediatric patients across multiple indications with age cutoffs (JIA aged 4 and older, plaque psoriasis aged 6 and older, Crohn's aged 6 and older, UC aged 5 and older, HS aged 12 and older). The treating paediatric specialist confirms eligibility.
• What if Cyltezo is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.

Closing

Reserve Meds runs the Cyltezo supply file from the SMC, BDF, or KHUH specialty referral through NHRA registration or named-patient pathway and delivered cold-chain supply. Clinical decisions remain with your treating specialist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.